Literature DB >> 20530700

The difficulty of targeting cancer stem cell niches.

Mark A LaBarge1.   

Abstract

Normal stem cell niches typically are identified by their distinctive anatomical features and by association with tissue-specific stem cells. Identifying cancer stem cell (CSC) niches presents a special problem because there are few if any common anatomical features among tumors, and the physical phenotypes that reportedly describe the CSCs as entities may be subject to the host's microenvironment, sex, and tumor stage. Irrespective of a niche's location, the occupant's phenotype, or the precise molecular composition, all niches must do basically the same thing: maintain the activities in a stem cell that define it as such. Therefore, a potentially successful strategy, both for elaborating a molecular and cellular portrait of a CSC niche, and for therapeutically targeting them, is to identify components in the tumor microenvironment that are required for maintaining the functions of self-renewal, differentiation, and quiescence in the face of cytotoxic therapeutic regimens. (c) 2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20530700      PMCID: PMC3182451          DOI: 10.1158/1078-0432.CCR-09-2933

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  80 in total

1.  Immediate transformation of solid into ascites tumors; studies on a mammary carcinoma of an inbred mouse strain.

Authors:  E KLEIN
Journal:  Exp Cell Res       Date:  1955-02       Impact factor: 3.905

2.  Methods of conditioning the graft in tumor transplantation.

Authors:  T S HAUSCHKA
Journal:  J Natl Cancer Inst       Date:  1953-12       Impact factor: 13.506

3.  Cell population studies on mouse ascites tumors.

Authors:  T S HAUSCHKA
Journal:  Trans N Y Acad Sci       Date:  1953-12

Review 4.  Hit 'em where they live: targeting the cancer stem cell niche.

Authors:  Zeng-Jie Yang; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

5.  Further research on transplantation of Yoshida sarcoma with single cell and with cell-free tumor ascites.

Authors:  K HOSOKAWA
Journal:  Gan       Date:  1950-12

6.  How does the extracellular matrix direct gene expression?

Authors:  M J Bissell; H G Hall; G Parry
Journal:  J Theor Biol       Date:  1982-11-07       Impact factor: 2.691

7.  The differentiated state of normal and malignant cells or how to define a "normal" cell in culture.

Authors:  M J Bissell
Journal:  Int Rev Cytol       Date:  1981

8.  The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.

Authors:  M D Sternlicht; A Lochter; C J Sympson; B Huey; J P Rougier; J W Gray; D Pinkel; M J Bissell; Z Werb
Journal:  Cell       Date:  1999-07-23       Impact factor: 41.582

9.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

Authors:  Catherine A O'Brien; Aaron Pollett; Steven Gallinger; John E Dick
Journal:  Nature       Date:  2006-11-19       Impact factor: 49.962

10.  Wounding and its role in RSV-mediated tumor formation.

Authors:  D S Dolberg; R Hollingsworth; M Hertle; M J Bissell
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

View more
  59 in total

Review 1.  Targeting Hedgehog--a cancer stem cell pathway.

Authors:  Akil A Merchant; William Matsui
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

2.  Controversies in cancer stem cells: targeting embryonic signaling pathways.

Authors:  Naoko Takebe; S Percy Ivy
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 3.  Targeting Notch to target cancer stem cells.

Authors:  Antonio Pannuti; Kimberly Foreman; Paola Rizzo; Clodia Osipo; Todd Golde; Barbara Osborne; Lucio Miele
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

4.  Treatment of agarose-agarose RENCA macrobeads with docetaxel selects for OCT4(+) cells with tumor-initiating capability.

Authors:  Lawrence S Gazda; Prithy C Martis; Melissa A Laramore; Melissa A Bautista; Atira Dudley; Horatiu V Vinerean; Barry H Smith
Journal:  Cancer Biol Ther       Date:  2013-09-12       Impact factor: 4.742

Review 5.  Cancer stem cells: progress and challenges in lung cancer.

Authors:  Amanda K Templeton; Shinya Miyamoto; Anish Babu; Anupama Munshi; Rajagopal Ramesh
Journal:  Stem Cell Investig       Date:  2014-04-15

Review 6.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

7.  The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells.

Authors:  Sang-Soo Kim; Antonina Rait; Farwah Rubab; Abhi K Rao; Michael C Kiritsy; Kathleen F Pirollo; Shangzi Wang; Louis M Weiner; Esther H Chang
Journal:  Mol Ther       Date:  2013-10-11       Impact factor: 11.454

Review 8.  Can we safely target the WNT pathway?

Authors:  Michael Kahn
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

Review 9.  Wnt signaling and the control of human stem cell fate.

Authors:  J K Van Camp; S Beckers; D Zegers; W Van Hul
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

Review 10.  Molecular deconstruction, detection, and computational prediction of microenvironment-modulated cellular responses to cancer therapeutics.

Authors:  Mark A Labarge; Bahram Parvin; James B Lorens
Journal:  Adv Drug Deliv Rev       Date:  2014-02-26       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.